Disruption of the murine procollagen C-proteinase enhancer 2 gene causes accumulation of pro-apoA-I and increased HDL levels

Journal of Lipid Research

Volumn 52, Issue 11, 2011, Pages 1974-1983

  Francone, Omar L ^a   Ishida, Brian Y ^b   De La Llera Moya, Margarita ^c   Royer, Lori ^a   Happe, Christiane ^d   Zhu, Jian ^a   Chalkey, Robert J ^b   Schaefer, Peter ^b   Cox, Cheryl ^b   Burlingame, Al ^b   Kane, John P ^b   Rothblat, George H ^c  

^a PFIZER INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

Apolipoprotein A I synthesis; Cholesterol efflux; High density lipoprotein metabolism; PCPE2

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; ASPARTYLGLUTAMYLPROPYLGLUTAMINYLSERYLGLUTAMINYLTRYPTOPHYLASPARTYLLYSINE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PEPTIDE DERIVATIVE; PROAPOLIPOPROTEIN A1; PROCOLLAGEN C PROTEINASE ENHANCER 2; PROTEIN PRECURSOR; TRYPTOPHYLHISTIDINYLVALYLTRYPTOPHYLGLUTAMINYLGLUTAMINYLASPARTYLGLUTAMYLPROPYLGLUTAMINYLSERYLGLUTAMINYLTRYPTOPHYLASPARTYLLYSINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIET; ELECTROPHORESIS; ELECTROPHORETIC MOBILITY; FEMALE; GENDER; GENE; GENE SILENCING; IN VIVO STUDY; ISOELECTRIC FOCUSING; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROCOLLAGEN C PROTEINASE ENHANCER 2 GENE; PROTEIN BLOOD LEVEL; PROTEIN PROCESSING; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; APOLIPOPROTEIN A-I; CHOLESTEROL; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLYCOPROTEINS; LIPOPROTEINS, HDL; MALE; MICE; MOLECULAR SEQUENCE DATA; PARTICLE SIZE;

EID: 80054117724     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M016527     Document Type: Article

References (39)

1. Robins, S. J., D. Collins, J. T. Wittes, V. Papademetriou, P. C. Deedwania, E. J. Schaefer, J. R. McNamara, M. L. Kashyap, J. M. Hershman, L. F. Wexler, et al. 2001. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA. 285: 1585-1591. (Pubitemid 32240250)
2. Manninen, V., M. O. Elo, M. H. Frick, K. Haapa, O. P. Heinonen, P. Heinsalmi, P. Helo, J. K. Huttunen, P. Kaitaniemi, P. Koskinen, et al. 1988. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 260: 641-651.
3. Tall, A. R., L. Yvan-Charvet, N. Terasaka, T. Pagler, and N. Wang. 2008. ABC transporters and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 7: 365-375. (Pubitemid 351598023)
4. Navab, M., S. T. Reddy, B. J. Van Lenten, and A. M. Fogelman. 2011. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 8: 222-232.
5. Goode, E. L., S. S. Cherny, J. C. Christian, G. P. Jarvik, and M. de Andrade. 2007. Heritability of longitudinal measures of body mass index and lipid and lipoprotein levels in aging twins. Twin Res. Hum. Genet. 10: 703-711. (Pubitemid 47608003)
6. Spirin, V., S. Schmidt, A. Pertsemlidis, R. S. Cooper, J. C. Cohen, and S. R. Sunyaev. 2007. Common single-nucleotide polymorphisms act in concert to affect plasma levels of high-density lipoprotein cholesterol. Am. J. Hum. Genet. 81: 1298-1303. (Pubitemid 350211459)
7. Teslovich, T. M., K. Musunuru, A. V. Smith, A. C. Edmondson, I. M. Stylianou, M. Koseki, J. P. Pirruccello, S. Ripatti, D. I. Chasman, C. J. Willer, et al. 2010. Biological, clinical, and population relevance of 95 loci for blood lipids. Nature. 466: 707-713.
8. Willer, C. J., S. Sanna, A. U. Jackson, A. Scuteri, L. L. Bonnycastle, R. Clarke, S. C. Heath, N. J. Timpson, S. S. Najjar, H. M. Stringhman, et al. 2008. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40: 161-169. (Pubitemid 351171403)
9. Xu, H., T. A. Acott, and M. K. Wirtz. 2000. Identification and expression of a novel type I procollagen C-proteinase enhancer protein gene from the glaucoma candidate region on 3q21-q24. Genomics. 66: 264-273. (Pubitemid 30481773)
10. Hinds, D. A., A. B. Seymour, L. K. Durham, P. Banerjee, P. G. Milos, D. R. Cox, J. F. Thompson, and K. A. Frazer. 2004. Application of pooled genotyping to scan candidate regions for association with HDL cholesterol levels. Hum. Genomics. 1: 421-434.
11. Zhu, J., J. Gardner, C. R. Pullinger, J. P. Kane, J. F. Thompson, and O. L. Francone. 2009. Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1. J. Lipid Res. 50: 1330-1339.
12. Steiglitz, B. M., D. R. Keene, and D. S. Greenspan. 2002. PCOLCE2 encodes a functional procollagen C-proteinase enhancer (PCPE2) that is a collagen-binding protein differing in distribution of expression and post-translational modification from the previously described PCPE1. J. Biol. Chem. 277: 49820-49830. (Pubitemid 36014430)
13. Weiss, T., S. Ricard-Blum, L. Moschcovich, E. Wineman, S. Mesilaty, and E. Kessler. 2010. Binding of procollagen C-proteinase enhancer-1 (PCPE-1) to heparin/heparin sulfate. Properties and role in pcpe-1 interaction with cells. J. Biol. Chem. 285: 33867-33874.
14. Bekhouche, M., D. Kronenberg, S. Vadon-Le Goff, C. Bijakowski, N. H. Lim, B. Font, E. Kessler, A. Colige, H. Nagase, G. Murphy, et al. 2010. Role of the netrin-like domain of procollagen C-proteinase enhancer-1 in the control of metalloproteinase activity. J. Biol. Chem. 285: 15950-15959.
15. Heinzel, K., and C. C. Bleul. 2007. The Foxn1-dependent transcripts PCOLCE2 and mPPP1R6B are not required for normal thymopoiesis. Eur. J. Immunol. 37: 2562-2571. (Pubitemid 47423625)
16. Chau, P., P. E. Fielding, and C. J. Fielding. 2007. Bone morphogenetic protein-1 (BMP-1) cleaves human proapolipoprotein A1 and regulates its activation for lipid binding. Biochemistry. 46: 8445-8450. (Pubitemid 47075981)
17. Aiello, R. J., D. Brees, P-A. Bourassa, L. Royer, S. Lindsey, R. Coskran, M. Haghpassand, and O. L. Francone. 2002. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler. Thromb. Vasc. Biol. 22: 630-637. (Pubitemid 34408745)
18. Zimetti, F., G. K. Weibel, M. Duong, and G. H. Rothblat. 2006. Measurment of cholesterol bidirectional flux between cells and lipoproteins. J. Lipid Res. 47: 605-613. (Pubitemid 43345601)
19. Asztalos, B. F., M. de la Llera-Moya, G. E. Dallal, K. V. Horvath, E. J. Schaefer, and G. H. Rothblat. 2005. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediatd cholesterol efflux. J. Lipid Res. 46: 2246-2253. (Pubitemid 41377476)
20. Adorni, M. P., F. Zimetti, J. T. Billheimer, N. Wang, D. J. Rader, M. C. Phillips, and G. H. Rothblat. 2007. The roles of different pathways in the release of cholesterol from macrophages. J. Lipid Res. 48: 2453-2462. (Pubitemid 350058756)
21. Sliwkowski, M. B., and H. G. Windmueller. 1984. Rat liver and small intestine produce proapolipoprotein A-I which is slowly processed to apolipoprotein A-I in the circulation. J. Biol. Chem. 259: 6459-6465. (Pubitemid 14108195)
22. Rajavashisth, T. B., P. A. Dawson, D. L. Williams, J. E. Shackelford, H. Lebherz, and A. J. Lusis. 1987. Structure, evolution and regulation of chicken apolipoprotein A-I. J. Biol. Chem. 262: 7058-7065.
23. Zannis, V. I., S. K. Karathanasis, H. T. Keutmann, G. Goldberger, and J. L. Breslow. 1983. Intracellular and extracellular processing of human apolipoprotein A-I: secreted apolipoprotein A-I isoprotein2 is a propeptide. Proc. Natl. Acad. Sci. USA. 80: 2574-2578. (Pubitemid 13093356)
24. Zannis, V. I., A. Chroni, and M. Krieger. 2006. Role of apoAI, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J. Mol. Med. 84: 276-294.
25. Stoffel, W. 1984. Synthesis, transport, and processing of apolipoproteins of high density lipoproteins. J. Lipid Res. 25: 1586-1592. (Pubitemid 15169477)
26. Januzzi, J. L., N. Azrolan, A. O'Connell, K. Aalto-Setala, and J. L. Breslow. 1992. Characterization of the mouse apolipoprotein Apoa-1/Apoc-3 gene locus: genomic, mRNA, and protein sequences with comparisons to other species. Genomics. 14: 1081-1088. (Pubitemid 23053049)
27. Castro, G. R., and C. J. Fielding. 1988. Early incorporation of cell-derived cholesterol into pre-beta migrating high-density lipoproteins. Biochemistry. 27: 25-29. (Pubitemid 18036281)
28. Holleboom, A. G., M. Vergeer, G. Kees Hovingh, J. J. P. Kastelein, and J. A. Kuivenhoven. 2008. The value of HDL genetics. Curr. Opin. Lipidol. 19: 385-394.
29. Thompson, J. F., C. L. Hyde, L. S. Wood, S. A. Paciga, D. A. Hinds, D. R. Cox, G. K. Hovingh, and J. J. P. Kastelein. 2009. Comprehensive whole genome and candidate gene analysis for response to statin therapy in TNT cohort. Circ. Cardiovasc. Genet. 2: 173-181.
30. Chasman, D. I., D. Posada, L. Subrahmanyan, N. R. Cook, V. P. Stanton, and P. M. Ridker. 2004. Pharmacogenomic study of statin therapy and cholesterol reduction. JAMA. 291: 2821-2827. (Pubitemid 38747801)
31. Thompson, J. F., M. Man, K. J. Johnson, L. S. Wood, M. E. Lira, D. B. Lloyd, P. Banerjee, P. M. Milos, S. P. Myrand, J. Pauluaskis, et al. 2005. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 5: 352-358.
32. Krauss, R. M., L. M. Mangravite, J. D. Smith, M. W. Medina, D. Wang, X. Guo, M. J. Rieder, J. A. Simon, S. B. Hulley, D. Waters, et al. 2008. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. 117: 1537-1544. (Pubitemid 351440642)
33. Demirkan, A., N. Amin, A. Isaacs, M-R. Jarvelin, J. B. Whitfield, H. E. Wichmann, K. O. Kyvik, I. Rudan, C. Gieger, A. A. Hicks, et al. 2011. Genetic architecture of circulating lipid levels. Eur. J. Hum. Genet. 19: 8 13-819.
34. Rye, K-A., C. A. Bursill, G. Lambert, F. Tabet, and P. J. Barter. 2009. The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50(Suppl.): S195-S200.
35. Rothblat, G. H., and M. C. Phillips. 2010. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol. 21: 229-238.
36. Khera, A. V., M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M. F. Burke, K. Jafri, B. C. French, J. A. Phillips, M. L. Mucksavage, R. L. Wilensky, et al. 2011. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364: 127-135.
37. McGuire, K. A., W. S. Davidson, and A. Jonas. 1996. High yield oerexpression and characterization of human recombinant proapolipoprotein A-I. J. Lipid Res. 37: 1519-1528. (Pubitemid 26249983)
38. Huang, W., A. Matsunaga, W. Li, H. Han, A. Hoang, M. Kugi, T. Koga, D. Sviridov, N. Fidge, and J. Sasaki. 2001. Recombinant proapoA-I (Lys107del) shows impaired lipid binding associated with reduced binding to plasma high density lipoprotein. Atherosclerosis. 159: 85-91. (Pubitemid 33016625)
39. Sviridov, D., L. Pyle, and N. Fidge. 1996. Efflux of cellular cholesterol and phospholipid to apolipoprotein A-I mutants. J. Biol. Chem. 271: 33277-33283. (Pubitemid 27010136)